MedTrace Logo

Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies

NCT00530972 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2009-09-07

No results posted yet for this study

Summary

To determine the efficacy and safety of Peginterferón alfa-2a (40 KD) plus Ribavirin in patients who have relapsed or not responded to a previous suboptimal therapy based in Interferon.

Conditions

  • Chronic Hepatitis C
  • HIV Infections

Interventions

DRUG

Peginterferon alfa-2a plus ribavirin adjusted to body weight

PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg \<75 kg, 1200 mg \>75 kg)

Sponsors & Collaborators

  • Hospital Carlos III, Madrid

    lead OTHER

Principal Investigators

  • Vicente Soriano, Dr · Hospital Carlos III. Madrid. Spain

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00530972 on ClinicalTrials.gov